# Benralizumab Patient Access Programme Study: Retrospective Study in UK Severe Asthma Centres

> **NCT05932849** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 276 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Benralizumab

## Key facts

- **NCT ID:** NCT05932849
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-05
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05932849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05932849, "Benralizumab Patient Access Programme Study: Retrospective Study in UK Severe Asthma Centres". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05932849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*